LoadingLoadingLoadingNet selling: insiders sold $4.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
Balyasny
$170.9M
added
Millennium
$151.2M
added
Squarepoint
$143.2M
added
No tracked top-trader positions in COR as of Oct 24, 10:57 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Financial period
Q3 FY2026
Earnings per share
$4.35 expected
Revenue
$84.15B expected
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $4.48 / $4.35Yahoo Finance | +3.04% beat | $84.80B $84.15B expected | +0.77% beat |
| Mar 31, 2026 | May 6, 2026 | $4.75 / $4.72Yahoo Finance | +0.65% in line | $78.36B No estimate | Unavailable |
| Dec 31, 2025 | Feb 4, 2026 | $4.08 / $4.04Yahoo Finance | +0.99% in line | $85.93B No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | $3.84 / $3.79Yahoo Finance | +1.44% beat | $83.73B No estimate | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | $4.00 / $3.84Alpha Vantage | +4.17% beat | $80.66B No estimate | Unavailable |
| Mar 31, 2025 | May 7, 2025 | $4.42 / $4.10Alpha Vantage | +7.80% beat | $75.45B No estimate | Unavailable |
| Dec 31, 2024 | Feb 5, 2025 | $3.73 / $3.52Alpha Vantage | +5.97% beat | $81.49B No estimate | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $3.34 / $3.22Alpha Vantage | +3.73% beat | $79.05B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $83.73B | $85.93B | $78.36B | $84.75B |
| Cost of what it sold | $81.13B | $83.12B | $75.03B | $81.15B |
| Gross profit | $2.60B | $2.81B | $3.32B | $3.61B |
| What it spent | ||||
| Sales and admin | $1.75B | $1.80B | $1.98B | $2.13B |
| Other operating costs | — | — | — | $354.6M |
| Total operating expenses | $1.75B | $1.80B | $1.98B | $2.49B |
| What was left | ||||
| Operating profit | $854.6M | $1.02B | $1.34B | $1.12B |
| Interest on debt | $109.4M | $93.4M | $154.3M | $140.7M |
| Profit before tax | -$187.0M | $708.6M | $2.09B | $996.4M |
| Tax | $146.0M | $142.5M | $459.0M | $219.7M |
| Net profit | -$339.7M | $559.6M | $1.64B | $763.5M |
| EBITDA | $183.3M | $1.04B | $2.50B | $1.42B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Pharma Pulse: Cencora to Acquire AON, Amazon and Google Back ePA Expansion
BullishOct 22Cencora making $2.4B acquisition as diversification push continues
BullishOct 21McKesson stock: UBS raises target to USD 1,200 for McKesson stock
NeutralOct 21Cardinal Health stock: Mizuho lifts target to USD 280.00 for Cardinal Health stock
NeutralOct 21Cardinal Health stock: Mizuho lifts target to USD 280.00 for Cardinal Health stock
NeutralOct 21Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE
NeutralOct 21Here’s How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
BullishOct 21Cencora to acquire American Oncology Network in $2.4 billion deal
Leans bullishOct 21
